All In Biotech

Drug Trial Radar · NCT06136598

A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)

A Phase 1 Clinical Study to Investigate the Safety and Pharmacokinetics of MK-5684 in China Participants With Metastatic Castration-Resistant Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Mar 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

14

Actual

Start

Jan 30, 2024

Primary completion

Mar 9, 2026

Study completion Mar 9, 2026

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
Orion Corporation, Orion Pharma
First posted
Nov 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives of this study are to evaluate the safety and tolerability of opevesostat in the treatment of male Chinese participants with metastatic castration-resistant prostate cancer (mCRPC) and to characterize the pharmacokinetic profile of opevesostat. There are no formal hypotheses to be tested in this study.

Conditions

  • Prostatic Neoplasms
  • Metastatic Castration-Resistant Prostate Cancer

Interventions

  • OpevesostatDrug

    Tablets to be taken orally.

  • DexamethasoneDrug

    Tablets to be taken orally

  • FludrocortisoneDrug

    Tablets to be taken orally.

  • HydrocortisoneDrug

    Tablet to be taken orally as a rescue medication.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 20 months
  2. Number of Participants Who Discontinue Study Intervention Due to an AETime frame: Up to approximately 20 months
  3. Maximum Plasma Concentration (Cmax) of opevesostatTime frame: Day 1 and Day 8: predose and 0.5, 1, 2, 3, 4, 6, 9, and 12 hours postdose, Day 29, Day 57, and Day 89: pre-dose
  4. Time to Maximum Plasma Concentration (Tmax) of opevesostatTime frame: Day 1 and Day 8: predose and 0.5, 1, 2, 3, 4, 6, 9, and 12 hours postdose, Day 29, Day 57, and Day 89: pre-dose
  5. Area Under the Curve from Time 0 to 12 hours postdose (AUC0-12) of opevesostatTime frame: Day 1 and Day 8: predose and 0.5, 1, 2, 3, 4, 6, 9, and 12 hours postdose, Day 29, Day 57, and Day 89: pre-dose
  6. Apparent Volume of Distribution (Vz/F) of opevesostatTime frame: Day 1 and Day 8: predose and 0.5, 1, 2, 3, 4, 6, 9, and 12 hours postdose, Day 29, Day 57, and Day 89: pre-dose
  7. Oral Clearance (CL/F) of opevesostatTime frame: Day 1 and Day 8: predose and 0.5, 1, 2, 3, 4, 6, 9, and 12 hours postdose, Day 29, Day 57, and Day 89: pre-dose
  8. Half-Life (t1/2) of opevesostatTime frame: Day 1 and Day 8: predose and 0.5, 1, 2, 3, 4, 6, 9, and 12 hours postdose, Day 29, Day 57, and Day 89: pre-dose

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University First Hospital-Urology ( Site 0001)

    Beijing, Beijing Municipality, China

  • Sun Yat-sen University Cancer Center-Neurosurgery department ( Site 0003)

    Guangzhou, Guangdong, China

  • Tongji Hospital Tongji Medical,Science & Technology ( Site 0002)

    Wuhan, Hubei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.